Allergy Shots vs Sublingual Drops for Common Indoor Allergens

At-home sublingual drops can be an alternative to allergy shots for adults with dust mite, pet dander, or mold allergies when a clinician finds them appropriate. Both routes retrain the immune system, but switching is a doctor-guided treatment decision. The choice depends on which allergens the treatment covers, how safe it is, what it costs, and whether daily home dosing or repeated clinic visits makes it possible to stay with treatment for three years.

Why dust mites, pet dander, and mold deserve their own immunotherapy conversation

Dust mites, pet dander, and mold can expose people throughout the year, so there may be no clear season when symptoms let up. Dust mite sensitization is the most prevalent among indoor allergens, with rates climbing higher among children and teenagers. Exposure includes both what is in the air outdoors and what a person encounters in the rooms where they spend each day and night.

Even homes without pets can contain enough airborne pet allergen to sensitize people, and cat allergen prevalence has gradually increased. Mold sensitization is also widespread, but symptoms are often attributed to something else. These sources can overlap, since most people with indoor allergies are sensitized to more than one indoor allergen. Naming just one trigger may leave some symptoms unexplained, even when dust mites, a pet, or mold is part of the cause.

How both allergy shots and sublingual drops retrain the immune system

Subcutaneous immunotherapy, or SCIT, delivers allergens through allergy shots, while sublingual immunotherapy, or SLIT, delivers them under the tongue as drops or tablets. Both give allergen doses that slowly increase to train the immune system to react less strongly. The route changes, but the biological aim does not. Unlike antihistamines and nasal sprays, these treatments seek to change the underlying allergic response rather than suppress symptoms only while medication is being used.

The WAO 2026 Position Paper supports SLIT’s ability to promote long-term immunological and clinical tolerance after treatment ends, a benefit also associated with SCIT. Neither route, however, delivers that benefit reliably through a short course. The three-year commitment is part of developing tolerance. This shared time horizon makes the practical differences between shots and drops important before treatment begins.

What the evidence actually shows when SCIT and SLIT go head to head

Does an injection work better because it feels like a more intensive treatment? Across allergic rhinitis symptom scores and medication use, SCIT and SLIT produce broadly comparable outcomes. Neither consistently outperforms the other across every measure and allergen. Jiumei Yang and Sihong Lei’s 2023 systematic review and meta-analysis in Frontiers in Immunology found no statistically significant differences in children’s symptom scores, medication scores, combined scores, or rates of new sensitizations. Those findings support a choice based on fit rather than an assumption that one route is always stronger.

Some comparative evidence suggests that SCIT provides greater improvements in certain seasonal allergic rhinitis measures. That pattern does not hold across all allergens or study designs, and it cannot simply be transferred to year-round indoor exposure. Similar results overall do not show that the evidence is the same for every tablet, compounded formula, and injection mixture. The particular allergen and formulation remain part of the comparison.

The meta-analysis in children also found significantly fewer treatment-related adverse events with SLIT than with SCIT. Effectiveness and tolerability are therefore separate questions, even when symptom outcomes look similar. Another distinction is between remission and cure. Both routes can produce long-term remission or meaningfully reduced sensitivity for many patients, but neither guarantees that everyone will become symptom-free. A useful comparison asks what each treatment can reasonably achieve and what completing it will require.

Allergen-specific coverage: where each route has an advantage

For dust mite allergy, the U.S. has an FDA-approved SLIT tablet called Odactra. Its label requires the first dose under medical supervision, followed by a 30-minute observation period, and a prescribed epinephrine auto-injector. Subsequent doses are taken daily at home throughout the year. This is a defined pathway for a specific allergen. It is not, however, a tablet that also treats pet dander or mold.

No FDA-approved SLIT tablet exists for cat or dog dander or mold, so U.S. patients seeking sublingual treatment for those allergens currently rely on compounded liquid drops. These drops are off-label rather than FDA-approved SLIT products. A customized formula can address dust mites, pet dander, and mold together, while SCIT can provide multi-allergen treatment through a custom-mixed injection extract.

All four FDA-approved SLIT tablets have boxed warnings for severe allergic reactions. Their contraindications include severe, unstable, or uncontrolled asthma, a prior severe systemic or local reaction to SLIT, and a history of eosinophilic esophagitis. Insurance introduces another divide, since approved tablets are more likely to be covered than compounded drops, which many U.S. insurers decline to cover.

The safety gap between the two routes and what it means in practice

SLIT has the more favorable overall safety profile. Severe systemic reactions are rare, and no fatalities have been reported with SLIT in the evidence described here. Its predominant adverse events are local reactions, including oral itching, throat irritation, and mouth edema, which typically diminish with continued dosing. That does not make it risk-free. The tablet warnings and first-dose precautions exist because a lower risk is not the same as no risk.

In Sandra Nora Gonzalez-Diaz and colleagues’ case series in the World Allergy Organization Journal, none of the children or adults who received SLIT for mite, grass, and weed pollen sensitization had local or systemic adverse reactions. That finding applies only to the patients in that series. SCIT, meanwhile, is a proven, widely used therapy with a small but real risk of anaphylaxis. Clinic-based injections and observation after every dose are how that risk is managed. The safety requirement is built into the delivery model.

FDA-approved SLIT tablets require supervision and a 30-minute observation window for the first dose, with epinephrine available, before subsequent dosing moves home. Compounded drops are a different formulation, so the tablet label should not be treated as their dosing or supervision protocol. A doctor-guided drop program needs its own instructions for treatment. For parents with young children, people far from an allergist, or adults unable to accommodate weekly appointments, home dosing can make a long course sustainable.

How untreated indoor allergies compound into larger health problems

Dust mite exposure is particularly troublesome during sleep. Allergens in bedding confront a sensitized person with reactions at the time when the body should be recovering. Allergic rhinitis can cause nasal congestion that forces mouth breathing, fragments sleep, and reduces restorative deep and REM sleep. The consequences need not remain confined to a blocked nose. Repeated disruption can accumulate into difficulties with attention, decision-making, and emotional regulation.

The bedroom connection helps explain why these effects can be missed. A person may notice daytime tiredness or poor concentration without connecting it to an allergic response that recurs at night. Exposure throughout the year can keep that cycle going long past a short pollen season. Sleep and daytime function are part of the health burden that gives the treatment decision its weight.

The position paper supports evidence that SLIT may prevent or reduce asthma onset in children and adolescents with allergic rhinitis, with 87.9% of World Allergy Organization panelists agreeing on that point. “May” is important because this is not a guarantee of prevention for an individual child. For families who face indoor allergens day after day, treatment can aim to change the course of allergic disease as well as ease each night’s congestion.

Why symptom-masking medications fall short as a long-term indoor allergen strategy

Can a daily pill do enough instead? Antihistamines, nasal sprays, and decongestants have a legitimate role in controlling symptoms, including acute flare-ups. They do not, however, retrain the immune response to dust mites, dander, or mold. As exposure continues, keeping symptoms in check can take ongoing work, while a course aimed at tolerance has an end.

Side effects make that distinction more than theoretical. First-generation antihistamines, including diphenhydramine and chlorpheniramine, cross the blood-brain barrier and can cause sedation, dry mouth, blurred vision, and urinary retention. Drowsiness is a practical concern for adults who drive or work. Second-generation antihistamines, including fexofenadine, loratadine, and cetirizine, were designed to reduce brain penetration and drowsiness risk. Fexofenadine shows the lowest sedation rates among these in the clinical research described in the notes, but none of them changes the underlying allergic tendency.

Oral decongestants also have limits as a continuing strategy. Pseudoephedrine and phenylephrine can raise blood pressure and heart rate, so taking them for a long time carries different risks from using them for short-term symptom relief. Medication risks vary, so it would be misleading to treat every allergy medicine as equally sedating or equally unsuitable for ongoing use. The central limitation is simpler. For someone who reacts to dust mites in their own bedroom, medicine may be needed to control symptoms from daily exposure without building lasting immune tolerance.

Can I switch from allergy shots to sublingual drops at home?

A doctor-guided switch can be a reasonable choice when repeated clinic visits make allergy shots difficult to sustain. The decision turns on allergen coverage, safety logistics, lifestyle compatibility, and access. For someone primarily sensitized to dust mites, the approved tablet offers a defined home-dosing pathway after the supervised first dose. For pet dander, mold, or several indoor allergens together, customized drops or custom-mixed shots offer broader coverage. The first task is matching treatment to the triggers actually driving symptoms.

A history of eosinophilic esophagitis or a severe SLIT reaction calls for careful assessment of whether sublingual treatment is appropriate. Uncontrolled asthma is not a reason to assume that shots are the safe substitute. SCIT remains a strong option for patients established in an allergist practice, able to attend observed injections, or whose insurance covers shots but not drops.

For suitable patients, doctor-guided SLIT programs can begin with a virtual consultation and at-home allergy testing, then provide a personalized drop formulation. That model combines customized allergen coverage with daily treatment at home, but it does not make compounded drops equivalent to an FDA-approved tablet. Cost and clinical instructions still need to fit. The chosen route needs to make three or more years of consistent treatment achievable, because lasting tolerance depends on completing the course.